<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002582</url>
  </required_header>
  <id_info>
    <org_study_id>NCRI-ABC</org_study_id>
    <secondary_id>CDR0000063697</secondary_id>
    <secondary_id>CRC-TU-BR3010</secondary_id>
    <secondary_id>SCTN-BR9401/BR9402</secondary_id>
    <secondary_id>YRCO-ABC</secondary_id>
    <secondary_id>EU-94029</secondary_id>
    <secondary_id>UKCCCR-ABC</secondary_id>
    <nct_id>NCT00002582</nct_id>
  </id_info>
  <brief_title>Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer</brief_title>
  <official_title>UKCCCR RANDOMISED TRIAL OF ADJUVANT ENDOCRINE THERAPY AND CHEMOTHERAPY IN WOMEN WITH EARLY BREAST CANCER, THE ADJUVANT BREAST CANCER (ABC) TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research Campaign Clinical Trials Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scottish Cancer Therapy Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yorkshire Regional Clinical Trials Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
      tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combination
      chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or
      die. Combining hormone therapy with chemotherapy may kill more tumor cells.

      PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without
      chemotherapy and/or ovarian ablation in treating women with stage I, stage II, or stage IIIA
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Estimate overall and relapse-free survival of women with early-stage breast cancer
           receiving adjuvant tamoxifen with or without adjuvant chemotherapy and/or ovarian
           suppression.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified by participating
      institution and choice of randomization option.

      Postmenopausal women are randomized to the first or second groups.

      Randomization for pre- and perimenopausal women is based on the clinician's judgement of
      appropriate adjuvant therapy (chemotherapy and/or ovarian suppression). Patients may be
      randomized as follows: among all four groups; for chemotherapy alone (first versus second
      group); for ovarian suppression alone (first versus third group); for ovarian suppression
      with nonrandomized assignment to chemotherapy (second versus forth group); for chemotherapy
      with nonrandomized assignment to ovarian suppression (second versus fourth group).

        -  First group: Patients receive tamoxifen by mouth every day for 5 years.

        -  Second group: Patients receive tamoxifen plus cyclophosphamide, methotrexate,
           fluorouracil (CMF) or doxorubicin/cyclophosphamide (AC). CMF is given every month for 6
           courses; AC is given every 3 weeks for 4 courses.

        -  Third group: Patients receive tamoxifen plus ovarian suppression by oophorectomy,
           radiation castration, or leuprolide or goserelin.

        -  Fourth group: Patients receive tamoxifen plus ovarian suppression plus chemotherapy with
           CMF or AC.

      Patients are followed for overall and relapse-free survival.

      PROJECTED ACCRUAL: Approximately 6,000 women (4,000 premenopausal, 2,000 postmenopausal) will
      be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1993</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMF regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>oophorectomy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive carcinoma of the breast for which adjuvant systemic
             therapy is appropriate

               -  Stage I, II, or IIIA

               -  Pathologically positive or negative nodes

               -  Any size primary tumor

          -  No edema, peau d'orange, infiltration of the skin, or direct extension to the chest
             wall

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Sex:

          -  Female

        Menopausal status:

          -  Pre-, peri-, or postmenopausal

        Performance status:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No prior malignancy except:

               -  Basal cell carcinoma

               -  Carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  See Disease Characteristics

        Chemotherapy:

          -  See Disease Characteristics

        Endocrine therapy:

          -  See Disease Characteristics

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No prior systemic treatment for breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R. Yarnold, MD, FRCR</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Earl, MBBS, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research Campaign Clinical Trials Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanley B. Kaye, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim J. Perren, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research Campaign Trials Unit-Birmingham (CRCTU)</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Perren TJ. Adjuvant therapy for operable breast cancer; more answers, new questions. Br J Cancer. 1995 Jun;71(6):1142-4. Review.</citation>
    <PMID>7779702</PMID>
  </reference>
  <reference>
    <citation>Brunt AM. The UKCCCR adjuvant breast cancer (ABC) trial. ABC Trial Steering Committee. Clin Oncol (R Coll Radiol). 1994;6(4):209-10.</citation>
    <PMID>7986756</PMID>
  </reference>
  <reference>
    <citation>Yarnold JR, Bliss JM, Brunt M, Earl H, Kaye S, Mason M, Mossman J, Perren T, Richards M. Management of breast cancer. Refer women to multidisciplinary breast clinics. BMJ. 1994 Mar 12;308(6930):714-5.</citation>
    <PMID>8142803</PMID>
  </reference>
  <reference>
    <citation>Bliss JM, Yarnold JR. Treatment of early breast cancer. Lancet. 1992 Apr 11;339(8798):936.</citation>
    <PMID>1348335</PMID>
  </reference>
  <results_reference>
    <citation>Adjuvant Breast Cancer Trials Collaborative Group. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):506-15.</citation>
    <PMID>17405995</PMID>
  </results_reference>
  <results_reference>
    <citation>Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):516-25.</citation>
    <PMID>17405996</PMID>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2003</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

